Additionally, AT2R blockade was shown to prevent thyroid hormone-induced cardiac mass gain and Akt activation, indicating the role of AT2R in developing future therapeutic strategies for the treatment of pathological cardiac hypertrophy [139]. This evidence concerns the gene AKT1 and cardiac hypertrophy.